Does Miglustat ameliorate isoproterenol-induced cardiac fibrosis?
Miglustat shows potential as a treatment for cardiac fibrosis by targeting UGCG and inhibiting associated signaling pathways.
Mig ameliorates β-AR overactivation-induced cardiac fibrosis by inhibiting ERK, STAT3, Akt and GSK3β signaling and UGCG may be a potential target for the treatment of cardiac fibrosis.
Liu et al. (Tue,) studied this question.